Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

VBL Therapeutics' VB-201 candidate delays onset of EAE, shows potential for MS, CNS treatment

Athersys signs agreement with RTI Biologics for MAPC technology access

Athersys signs agreement with RTI Biologics for MAPC technology access

Santarus expands development pipeline, adds two novel biologic drug candidates

Santarus expands development pipeline, adds two novel biologic drug candidates

NIH announces award to improve human microbiome research

NIH announces award to improve human microbiome research

Researchers dispute study findings that show greater incidence of surgery for children with CD

Researchers dispute study findings that show greater incidence of surgery for children with CD

Research finds link between chronic heart failure, iron deficiency

Research finds link between chronic heart failure, iron deficiency

Prometheus launches Crohn's Prognostic test

Prometheus launches Crohn's Prognostic test

Plantain and broccoli fiber help in Crohn’s disease: Study

Plantain and broccoli fiber help in Crohn’s disease: Study

Study finds occurrence of low BMD in inflammatory bowel disease patients

Study finds occurrence of low BMD in inflammatory bowel disease patients

USPTO allows Regulus Therapeutics' claims of key Tuschl III patent covering Mir-155

USPTO allows Regulus Therapeutics' claims of key Tuschl III patent covering Mir-155

Athersys second-quarter revenues increase to $1.9 million

Athersys second-quarter revenues increase to $1.9 million

Apte wins Elkeles Prize for outstanding scientist in field of medicine

Apte wins Elkeles Prize for outstanding scientist in field of medicine

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

Targacept licenses Cornerstone technology for inflammatory disorders program

Targacept licenses Cornerstone technology for inflammatory disorders program

PHD1 useful for pharmacologic inhibition in IBD: Research

PHD1 useful for pharmacologic inhibition in IBD: Research

FDA approves N30 Pharma's NDA for N6022 GSNOR

FDA approves N30 Pharma's NDA for N6022 GSNOR

Study explores role of genetic influence on ulcerative colitis

Study explores role of genetic influence on ulcerative colitis

Immunosuppressive properties of TNF blockers may increase risk of malignancy in children

Immunosuppressive properties of TNF blockers may increase risk of malignancy in children

TNF blockers may increase the risk of malignancy in children

TNF blockers may increase the risk of malignancy in children

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

Positive results from phase I clinical trial of MultiStem in patients with AMI announced

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.